Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the analgesic efficacy, safety and tolerability of multiple doses of JNJ-42160443 when administered as a single, subcutaneous injection every 28 days to patients with diabetic painful neuropathy (a disease condition in diabetic patients that affects all peripheral nerves including pain fibers, motor neurons and the autonomic nervous system).


Clinical Trial Description

This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), dose-ranging study (study carried out at different doses) to evaluate the analgesic efficacy, safety, and tolerability of multiple doses of JNJ-42160443 in patients with neuropathic pain, followed by a double-blind safety extension and an open-label (all people know the identity of the intervention) safety extension. The study will consist of 5 sequential phases: 1) screening, 2) a 12-week double-blind efficacy, 3) a 40-week double-blind safety extension, 4) a 52-week open-label safety extension, and 5) a 26-week post-treatment/follow-up. After the screening phase, patient randomization will be stratified by current pain medication use (patients who are currently using or who are not currently using permitted pain medication). The planned doses for the double-blind efficacy phase and double blind safety extension phase are placebo, JNJ-42160443 1, 3, or 10 mg administered as a single, subcutaneous injection every 28 days. Safety assessment will include adverse events, injection site evaluations, clinical laboratory tests, electrocardiogram, vital signs, physical examinations, neurological examinations, and joint safety which will be monitored throughout the study. The total study duration (including all the 5 phases) will be approximately 131 weeks. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00993018
Study type Interventional
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status Terminated
Phase Phase 2
Start date November 2009
Completion date June 2011

See also
  Status Clinical Trial Phase
Completed NCT04025320 - The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy N/A
Completed NCT02659007 - Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga Phase 1
Completed NCT01953757 - A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2) N/A
Completed NCT01707979 - NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes N/A
Completed NCT00608439 - Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy Phase 2
Completed NCT00576277 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain Phase 1/Phase 2
Completed NCT00830011 - Cognitive Behavioral Therapy for Painful Diabetic Neuropathy N/A
Completed NCT00235443 - A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy Phase 2/Phase 3
Completed NCT00931879 - Lovaza® and Microvascular Function in Type 2 Diabetes Phase 4
Completed NCT00101426 - Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Phase 3
Completed NCT00190970 - The Effect of Ruboxistaurin on Small Fiber Function Phase 2
Completed NCT00238550 - Study of CBME in the Relief of Painful Diabetic Neuropathy Phase 2
Completed NCT05573685 - Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training N/A
Recruiting NCT02341261 - Activity for Diabetic Polyneuropathy N/A
Completed NCT01822925 - Study of DA-9801 to Treat Diabetic Neuropathy Phase 2
Completed NCT01690962 - A Nutritional Intervention for Diabetic Neuropathy N/A
Withdrawn NCT02315235 - The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy N/A
Completed NCT00496457 - Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy Phase 2
Recruiting NCT02606747 - The Balance Control Mechanism of DPN Patients N/A
Completed NCT02068027 - Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy Phase 2